China�� stocks rose the most in a week, led by consumer and technology companies, after the government called for deepening economic reform including measures to boost domestic consumption.
Retailer Shanghai Metersbonwe Fashion and Accessories Co. jumped 10 percent, driving a rally for consumer companies reliant on economic growth, after Shenyin & Wanguo Securities recommended buying the stock on the outlook for earnings next year. Shanghai Baosight Software Co. led gains for technology shares after signing a contract to provide data center services to Alibaba Group Holding Ltd. Jiangxi Copper Co. and Yunnan Copper Industry Co. slid at least 1 percent as rising copper stockpiles indicated slowing demand.
The Shanghai Composite Index (SHCOMP) climbed 0.5 percent to 2,203.92 as of 11:11 a.m. local time. The CSI 300 Index added 0.5 percent to 2,439.24. The Hang Seng China Enterprises Index (HSCEI) added 0.6 percent. The Shanghai Composite has risen 13 percent from its four-year low on June 27 and trades at 8.7 times projected earnings for the next 12 months, compared with the seven-year average of 15.4, according to data compiled by Bloomberg.
Hot Penny Companies To Invest In Right Now: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 34.74 percent to $35.15 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Top 5 Rising Stocks For 2014: Puma Exploration Inc (PUM)
Puma Exploration Inc. is a mineral exploration company. The Company is engaged in the acquisition and exploration of mining properties with the potential to host base-metal deposits. It is active in Canada and has a portfolio of mining properties. The Company�� properties include Nicholas-Denys, Ann�� Creek property, Turgeon property, Little Stull Lake Property and Ste-Marguerite Property. Its Nicholas-Denys area consists of 239 contiguous claims with a total surface area of 51.94 square kilometers and is 100% owned by the Company. The Company holds 100% mineral rights in Ann�� Creek area, which consists of 117 claims with a total area of 25.44 square kilometers. It holds 71% of the Little Stull Lake property located in the Stull Lake-Edmund Lake volcano-sedimentary belt of the Superior to Manitoba geologic province. The Ste-Marguerite property is located in the Vallee de la Matapedia, in Quebec. Advisors' Opinion:- [By Jonathan Morgan]
HeidelbergCement AG (HEI) added 3.2 percent after JPMorgan Chase & Co. upgraded the shares. Puma SE (PUM) slipped 1.6 percent after Europe�� second-largest sporting-goods maker reported earnings before interest and taxes for the second quarter that missed analysts��estimates.
Top 5 Rising Stocks For 2014: Immunomedics Inc.(IMMU)
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pany also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Immunomedics (IMMU), which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is off to a very bullish start in 2013, with shares up sharply by 110%.
If you take a look at the chart for Immunomedics, you'll notice that this stock has been uptrending decent for the last month, with shares moving higher from its low of $4.85 to its recent high of $6.54 a share. During that uptrend, shares of IMMU have been consistently making higher lows and higher highs, which is bullish technical price action. This uptrend is coming after shares of IMMU downtrended during July from $6.91 to that $4.65 a share low. Shares of IMMU are now starting to push within range of triggering a big breakout trade.
Market players should now look for long-biased trades in IMMU if it manages to break out above some near-term overhead resistance at $6.54 a share and then once it clears its 52-week high at $6.91 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.15 million shares. If that breakout triggers soon, then IMMU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $8 to $10 a share, or possibly even north of $10 a share.
Traders can look to buy IMMU off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.52 a share or below more support at $5 a share. One can also buy IMMU off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 5 Rising Stocks For 2014: Red Robin Gourmet Burgers Inc.(RRGB)
Red Robin Gourmet Burgers, Inc., together with its subsidiaries, develops, operates, and franchises casual-dining restaurants in the United States and Canada. As of February 16, 2012, the company operated 465 Red Robin restaurants, including 328 company-owned restaurants and 137 restaurants operating under franchise agreements. Its restaurants offer gourmet burgers, as well as various salads, soups, appetizers, entrees, desserts, and signature Mad Mixology alcoholic and non-alcoholic specialty beverages Red Robin Gourmet Burgers, Inc. was founded in 1969 and is headquartered in Greenwood Village, Colorado.
Advisors' Opinion:- [By Lisa Levin]
Red Robin Gourmet Burgers (NASDAQ: RRGB) shares climbed 3.04% to $54.23. The volume of Red Robin shares traded was 398% higher than normal. On Thursday, Red Robin reported downbeat second-quarter profit.
- [By Dan Caplinger]
Still, the stock's performance reflects overall enthusiasm about restaurant chains generally. Red Robin Gourmet Burgers (NASDAQ: RRGB ) struggled mightily during the recession, but its stock has bounced back convincingly, with gains sending shares to levels not seen since 2005. Even Brinker International (NYSE: EAT ) , which cut its estimates on same-store sales growth to just 1%, and guided earnings to the lower end of its previous range, has seen its stock soar in anticipation of better times ahead.
- [By Damian Illia]
Burger fans probably know Red Robin Gourmet Burgers Inc. (RRGB). Founded in Seattle, Red Robin Gourmet Burgers is a full-service casual dining restaurant chain that operates franchises and develops restaurants under the name of Red Robin Gourmet Burgers. By October 2013, Red Robin operated 350 company-owned restaurants and 135 franchised restaurants across the US and Canada. This burger-loving firm not only serves a broad variety of burgers made from beef, chicken, fish, pork and turkey, as well as veggie patties, but also offers salads, sandwiches, soups, entrees and the famous all-you-can-eat steak fries. Furthermore, a limited service non-traditional prototype restaurant is being developed by the company, named Red Robin�� Burger Works.
No comments:
Post a Comment